Document is current
Any future updates will be listed below
-
Authors
Weiner, Sophia https://orcid.org/0009-0000-2298-220X
Sauer, Mathias
Montoliu-Gaya, Laia
Benedet, Andrea L.
Ashton, Nicholas J.
Gonzalez-Ortiz, Fernando
Simrén, Joel
Rahmouni, Nesrine
Tissot, Cecile
Therriault, Joseph
Servaes, Stijn
Stevenson, Jenna
Leinonen, Ville
Rauramaa, Tuomas
Hiltunen, Mikko
Rosa-Neto, Pedro
Blennow, Kaj
Zetterberg, Henrik
Gobom, Johan
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2023-00356, 2022-01018, 2019-02397, ALFGBG-71320)
HORIZON EUROPE Reforming and enhancing the European Research and Innovation system (101053962)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C, ADSF-24-1284328-C, ADSF-24-1284326-C)
European Partnership on Metrology (22HLT07)
Hjärnfonden (FO2022-0270)
HORIZON EUROPE Marie Sklodowska-Curie Actions (860197)
EU Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute (UKDRI-1003)
Sigrid Juséliuksen Säätiö (339767, 338182, 355604)
University of Gothenburg
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 14 April 2025
First Online: 6 May 2025
Declarations
:
: The TRAID biomarker study was approved by the Montreal Neurological Institute PET working committee and the Douglas Mental Health University Institute Research Ethics Board. Written informed consent was obtained for all participants.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.
